Clinical Trial Update: Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VRC01 antibody for reducing acquisition of HIV-1 infection in women has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC01 (VRC01)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2022-02-08